Personalis reports Q2 EPS (23c), consensus (24c)

Reports Q2 revenue $17.2M, consensus $20.1M. “The results of our ‘Win-in-MRD’ strategy are clear, with an impressive 59% sequential growth in our clinical test volume,” said Chris Hall, Chief Executive Officer and President of Personalis (PSNL). “This powerful adoption trend is fueled by a continuous flow of compelling clinical data, like our recent landmark ASCO presentations, which prove the unique value of our ultra-sensitive MRD platform in guiding patient care. Steady recognition and growth in the use of our platform continues to support our strategy as we navigate the temporary headwinds in the biopharma sector which have affected our current results. Our fundamental growth engine is accelerating, keeping us firmly on track to achieve our most critical strategic objectives for 2025, including securing Medicare coverage for two indications.”